A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Quarterly and Monthly TOUR006 in Participants With Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein

This study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney disease and elevated hs-CRP.

开始日期2024-05-15

申办/合作机构

Tourmaline Bio, Inc.

NCT06088979

/ Recruiting临床2期

A Multicenter Phase 2b Randomized, Double-Masked, Placebo-Controlled Dose-Ranging Study of TOUR006 in Participants With Thyroid Eye Disease

Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.

开始日期2024-02-19

申办/合作机构

Tourmaline Bio, Inc.

NCT01287897

/ Completed临床2期

A Double-blind, Randomized, Placebo-controlled, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-04236921 In Subjects With Crohn's Disease Who Are Anti-tnf Inadequate Responders (Andante)

This is a proof of concept study to determine the efficacy and safety of a monoclonal antibody with three doses versus placebo. Subjects will be randomized to a treatment and the dose will be delivered subcutaneously twice, 4 weeks apart. All subjects will have moderate to severe refractory Crohn's Disease.

开始日期2011-02-01

申办/合作机构

Pfizer Inc.

100 项与帕西贝库单抗相关的临床结果

登录后查看更多信息

100 项与帕西贝库单抗相关的转化医学

登录后查看更多信息

100 项与帕西贝库单抗相关的专利（医药）

登录后查看更多信息

项与帕西贝库单抗相关的文献（医药）

2019-01-01·Gut1区 · 医学

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)

1区 · 医学

Article

作者: Cheryl Li ; Rupert W Leong ; Gerhard Rogler ; Mary K Maguire ; Fabio Cataldi ; Séverine Vermeire ; Gerald Fraser ; Silvio Danese ; Paul Hellstern ; Gail M Comer ; Anindita Banerjee ; Jean Beebe ; Anna Kohn ; Stefan Schreiber ; Natalie Rath ; Remo Panaccione ; Pierre Desreumaux

Objective:

Neutralising pro-inflammatory interleukin-6 (IL-6) may effectively treat Crohn’s disease (CD). Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD are reported.

Design:

Parallel-group, dose-ranging, double-blind trial with 4-week screening and 12-week treatment periods. After induction, patients entered 28-week follow-up or 48-week open-label extension (OLE) with 28-week follow-up. Adults with confirmed CD and inadequate response to anti-tumour necrosis factor (TNF) therapy were included. Induction study: 249 patients randomised 1:1:1:1 to placebo, PF-04236921 10, 50 or 200 mg by subcutaneous injection on days 1 and 28. OLE study: PF-04236921 50 mg every 8 weeks up to six doses followed by 28-week follow-up.

Results:

247 patients were randomised and received treatment in the induction study. The 200 mg dose was discontinued due to safety findings in another study (NCT01405196) and was not included in the primary efficacy analysis. Crohn’s Disease Activity Index (CDAI)-70 response rates with PF-04236921 50 mg were significantly greater than placebo at weeks 8 (49.3% vs 30.6%, P<0.05) and 12 (47.4% vs 28.6%, P<0.05) and met the primary end point. Week 12 CDAI remission rates with PF-04236921 50 mg and placebo were 27.4% and 10.9%, respectively (16.5% difference; P<0.05). 191 subjects received treatment in the OLE. Common treatment-emergent and serious adverse events in both studies included worsening CD, abdominal pain and nasopharyngitis.

Conclusions:

PF-04236921 50 mg induced clinical response and remission in refractory patients with moderate-to-severe CD following failure of anti-TNF therapy. GI abscess and perforation were observed, a specific focus of attention during future clinical development.

Trial registration number:

NCT01287897 and NCT01345318.

2017-03-01·Annals of the rheumatic diseases1区 · 医学

Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial

1区 · 医学

Article

作者: Eimon, Alicia ; Sridharan, Sudhakar ; Diehl, Annette ; Merrill, Joan T ; Healey, Paul ; Petri, Michelle ; Strand, Vibeke ; Wajdula, Joseph ; Beebe, Jean ; Li, Cheryl ; Christensen, Jared ; Spindler, Alberto J ; Popa, Serghei ; Wallace, Daniel J ; Vincent, Michael S ; Smolen, Josef S

Objectives:

This phase II trial evaluated the efficacy and safety of an interleukin (IL) 6 monoclonal antibody for systemic lupus erythematosus (SLE).

Methods:

Patients with active disease were randomised to placebo or PF-04236921 10 mg, 50 mg or 200 mg, subcutaneously, every 8 weeks with stable background therapy. SLE Responder Index (SRI-4; primary end point) and British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) were assessed at week 24. Post hoc analysis identified an enriched population based upon planned univariate analyses.

Results:

183 patients received treatment (placebo, n=45; 10 mg, n=45; 50 mg, n=47; 200 mg, n=46). The 200 mg dose was discontinued due to safety findings and not included in the primary efficacy analysis. The SRI-4 response rates were not significant for any dose compared with placebo; however, the BICLA response rate was significant for 10 mg (p=0.026). The incidence of severe flares was significantly reduced with 10 mg (n=0) and 50 mg (n=2) combined versus placebo (n=8; p<0.01). In patients with greater baseline disease activity (enriched population), the SRI-4 (p=0.004) and BICLA (p=0.012) response rates were significantly different with 10 mg versus placebo. Four deaths (200 mg, n=3; 10 mg, n=1) occurred. The most frequently reported adverse events included headache, nausea and diarrhoea.

Conclusions:

PF-04236921 was not significantly different from placebo for the primary efficacy end point in patients with SLE. Evidence of an effect with 10 mg was seen in a post hoc analysis. Safety was acceptable for doses up to 50 mg as the 200 mg dose was discontinued due to safety findings.

Trial registration number:

NCT01405196; Pre-results.

Frontiers in immunology

Model-Based Meta-Analysis on the Efficacy of Biologics and Small Targeted Molecules for Crohn’s Disease

Review

作者: Wang, Xiaoling ; Zhao, Libo ; Yu, Boran ; Jin, Siyao ; He, Huan ; Zhang, Jing

Information on comparative drug efficacy is of great importance for drug development as well as clinical practice. Up to now, the relative efficacy of biologics and small targeted molecules for Crohn’s disease (CD) remains unclear. The objective of this study was to quantify the relative efficacy of investigational and approved biological treatments for CD measured in Crohn’s Disease Activity Index (CDAI), Inflammatory Bowel Disease Questionnaire (IBDQ), and C-reactive protein (CRP). The analysis dataset was composed of summary-level data from 46 trials, containing 12,846 patients, with treatment of 24 drugs. Six mathematical models with non-parametric placebo estimations were developed to describe the time course and dose–response of six efficacy measures. The effects of covariate were further evaluated. Time–response relationships were found in outcomes measured in CDAI. The patients’ age, disease duration, baseline CDAI, and CRP showed an impact on the efficacy. Model simulations were performed to compare the efficacies across different drugs. The most achievement in clinical remission (defined as CDAI less than 150) and clinical response (defined as the reduction in CDAI for 100 or 70) was observed in the simulation for PF-04236921 and infliximab, respectively. The most improvement in IBDQ was shown in tofacitinib. In general, tumor necrosis factor (TNF)-α inhibitors were the most effective biologics, and the highest efficacy of small targeted molecules was observed in janus kinase (JAK) inhibitors. These findings have important implications for clinical practice in CD.

项与帕西贝库单抗相关的新闻（医药）

2026-02-18

·EndPoints

Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfront

CSL will need more than $100 million to recover from its current difficulties , but it’s a start. Eli Lilly has paid the nine-figure sum upfront for rights to the Australian company’s anti-IL-6 monoclonal antibody in unspecified indications. The drug is called clazakizumab, and CSL is developing it for patients with end-stage kidney disease who are on dialysis and at risk of major cardiovascular events. A placebo-controlled Phase 2/3 trial in more than 2,000 patients is ongoing, but will not generate data until 2029. CSL is keeping exclusive rights to develop and sell clazakizumab in this indication. What Lilly is planning for the molecule is less clear. CSL’s head of R&D Bill Mezzanotte said in a Wednesday press release that the drug has potential in “various immuno-inflammatory and cardiovascular conditions,” but the US drugmaker has not set out its development plans. Lilly could make further payments to CSL if the drug hits clinical, regulatory and commercial milestones, as well as royalties on global sales. These amounts were not specified, but CSL’s investors will have to hope the payments are frequent and generous. A week ago, the company released its financials for the six months ended Dec. 31, and they made for tough reading. Its net profit collapsed 81% from the prior year and it took $1.1 billion in write-downs, including for its $200 million upfront licensing agreement with Arcturus Therapeutics for Covid-19 and other vaccines. CSL’s CEO Paul McKenzie had left the day before , with the company’s chair saying McKenzie “didn’t have the skills that we wanted for the future.” IL-6-targeting antibodies have been the subject of dealmaking elsewhere. Last fall, Novartis bought Tourmaline Bio to get a hold of pacibekitug, which had shown promise in atherosclerotic cardiovascular disease. Pacibekitug is also in a mid-stage trial in thyroid eye disease, so perhaps this could be an avenue for Lilly to explore. Novo Nordisk also has an IL-6 candidate, which is called ziltivekimab. CSL obtained clazakizumab through its acquisition of Vitaeris for an unspecified amount in 2020.

引进/卖出疫苗并购信使RNA临床研究

2025-12-02

·丁香园 Insight 数据库

诺华心血管帝国再造

在肿瘤、自免赛道内卷加剧的当下，心血管领域在 MNC 战略布局中的地位正迅速攀升。Insight 数据库显示，近些年，MNC 作为受让方在该领域的医药交易数量逐年增长，并在今年创下了新高。截图来源：Insight 数据库诺华作为该领域的资深玩家，其心血管业务近三年来持续位居公司各大业务板块增速榜首，其王牌产品 Entresto（沙库巴曲缬沙坦，诺欣妥）的突出贡献功不可没。然而辉煌之下，危机已悄然浮现。随着 Entresto 迎来专利悬崖，叠加美国医保的「灵魂砍价」，诺华正在为其心血管领域寻找新的增长点。王牌产品的辉煌与隐忧作为全球首个血管紧张素受体脑啡肽酶抑制剂（ARNI），Entresto 被誉为心衰领域近 20 年来的突破性药物，同时它也是首个能够全程覆盖心血管前期高危因素高血压到心血管终末端心衰的创新药。在获批心衰适应症不到一年的时间内，Entresto 就被美国和欧洲的心力衰竭指南评为 I 类强推荐药物。2023 年，《中国高血压防治指南》也首次把 ARNI 作为新一类常用降压药物，而彼时 Entresto 是唯一获批的 ARNI 类创新药。从销售数据来看，上市三年 Entresto 就成功突破了十亿美元大关，2023 年销售额以 60 亿美元的销售额反超诺华另一款重磅产品司库奇尤单抗（49.80 亿美元），2024 年全球销售额攀升到 78.22 亿美元，成为诺华的销冠。图片来源：Insight 数据库整理凭借这款明星产品，诺华在心血管领域已经建立了强大的市场地位。但辉煌之下，危机已然出现。一方面来自于价格压力。2024 年，Entresto 被纳入《通货膨胀削减法案》下首批受医疗保险协商价格约束的药物之一，降价幅度达到 53%，利润空间将被挤压。另一方面，最大的威胁实际来自于专利悬崖。在美国，Entresto 于今年年中到期，目前包括印度瑞迪博士实验室、MSN、印度鲁宾等多家公司的 Entresto 仿制药已经获得 FDA 批准上市，虽然诺华已经与大多数仿制药企达成了和解，但是今年 7 月美国联邦法院驳回了诺华阻止 MSN 制药销售 Entresto 仿制药的请求。在中国，Entresto 的核心专利有效期至 2026 年，但根据 Insight 数据库统计，已经有来自 30 家国内药企的仿制药通过了一致性评价，伺机蚕食 Entresto 的市场份额。仿制药的冲击已初显端倪，Entresto 在今年第三季度销售额首次出现 1% 的下滑。根据 LSEG 数据，分析师预测到 2026 年 Entresto 的销售额将降至约 60 亿美元。事实上，仿制药的到来威胁的并不只关乎这一明星产品，更是动摇了诺华整个心血管帝国的根基。毕竟长期以来，Entresto 贡献了诺华心血管板块九成左右的收入。而 Leqvio 作为诺华心血管领域唯二的商业化产品，2024 年该药总销售额达 7.54 亿美元，同比增长率超过了 100%。2025 年上半年，Leqvio 收入达 5.55 亿美元，同比增长 67%，今年有望突破 10 亿美元大关。诺华的预测其销售额峰值有望达到 40 亿美元。截图来源：诺华高层见面会 PPT 但就短期而言，Leqvio 的增长数据并不能完全填补 Entresto 即将留下的收入缺口，也难以一力承托起诺华整个心血管板块的未来。如今，诺华的心血管帝国，正处在传承与更迭的关键时刻。百亿美元再造心血管帝国面对专利危机，交易并购无疑是 MNC 最直接的应对策略之一。诺华也不例外，其正通过积极的外延式布局，重构其心血管防线。根据 Insight 数据库，2025 年以来，诺华作为受让方一共达成了 13 笔医药交易，总金额超过 360 亿美元，其中心血管领域成为一大重点布局方向，已经砸下了超百亿美元。在技术路径上，诺华明显向小核酸疗法倾斜。此前引进的 Leqvio 让诺华尝到了甜头，这款全球首创的 siRNA 药物在治疗高脂血症上初显成效，证明了小核酸技术在心血管慢病管理领域的巨大潜力。今年 9 月，诺华和舶望制药达成了一笔超 50 亿美元的合作，引进了后者多款心血管领域的 siRNA 候选药物。这并非双方首次牵手，去年二者就已经在多个 RNAi 项目上达成了许可协议及战略合作。两次投入近百亿美元，诺华正是看中了 RNAi 技术对其心血管领域的强大助力。此前，诺华还从 Ionis 引进了一款靶向载脂蛋白（Apoa）mRNA 的反义寡核苷酸（ASO）疗法 Pelacarsen。该药能抑制 Lp(a) 在肝脏中的合成，从而降低心血管疾病的风险，目前正在开展针对降低心血管风险、Lp(a) 血症、动脉粥样硬化的 III 期临床。诺华对其寄予厚望，将其列为八大潜在价值数十亿美元的分子之一。截图来源：诺华高层见面会 PPT 从靶点布局来看，过去三年全球心血管新药研发的热门靶点主要集中在 PCSK9、Lp(a)、GLP-1。Pacibekitug 则代表了一种全新的治疗思路，这是诺华今年 9 月以 14 亿美元收购 Tourmaline Bio 获得了一款 IL6 单抗，能够通过靶向炎症来治疗动脉粥样硬化性心血管疾病（ASCVD）。相比现有疗法，Pacibekitug 能更有效地解决残留炎症风险这一未被满足的需求。与此同时，诺华也在积极寻找同类首创的机会。今年早些时候，诺华以最高 31 亿美元收购 Anthos Therapeutics（由诺华和黑石生命科学创立）获得了靶向 FXI 的潜在同类首创单抗疗法 Abelacimab，丰富了研发后期的心血管项目。 II 期 AZALEA 结果显示，相比于标准治疗利伐沙班，Abelacimab 在降低房颤患者出血事件发生率方面具有显著优势。目前，该药正在进行三项 III 期临床试验，未来有望实现几十亿美金的峰值销售。在战略层面，诺华更展现出了长线思维。今年 6 月，诺华和 ProFound Therapeutics 达成了一项为期四年的合作协议，目标就是利用后者的 ProFoundry 平台挖掘人类蛋白质组中的新型药物靶点，推动心血管疾病创新药物发现。纵观诺华整体的心血管研发管线，其布局正呈现出一种层次分明、持续接力的健康态势，形成了一个覆盖近期、中期、远期的立体化产品梯队。预计到 2030 年，诺华将有 4 项重要的 III 期（不包含肾病领域）数据读出，标志着其心血管管线进入了关键的「收获验证期」与「价值兑现阶段」。截图来源：诺华高层见面会 PPT 值得一提的是，在心血管领域，诺华作为业内少数深耕心脏节律这一方向的药企之一，正致力于为心律失常患者提供以药物代替设备的创新解决方案。目前诺华正加速推进包括 HDAC 抑制剂在内的多款候选药物进入临床，目标是构建一整套针对房颤的完整药物管线，未来其布局还可能延伸至室性心律失常等领域。小结诺华的心血管故事，正迎来最关键的转折章回。从 siRNA 平台到靶向炎症，诺华正用新一轮技术周期，证明自己不是心血管领域「过去的王者」，而是「未来的守门人」。参考资料： 1. 诺华的财报、公告、官微 2. 丁香园 Insight 数据库封面来源：企业 Logo 免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。编辑：ccai PR 稿对接：微信 insightxb 投稿：微信 insightxb；邮箱 insight@dxy.cn

2025-12-02

·GlobeNewswire-Health Care

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

BOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that it intends to develop its fully human anti-IL-6 receptor (IL-6R) monoclonal antibody, TZLS-501, and related assets (together “TZLS-501”) via a spinout into a separate publicly traded company, to enhance the strategic focus of each company and to drive value for shareholders. Tiziana shareholders at the record date will retain value from TZLS-501 through the distribution in specie of shares in the new TZLS-501 listed entity. The Company recently announced that it would advance development of TZLS-501, a dual-action IL-6R monoclonal antibody targeting both membrane-bound and soluble forms of IL-6R. This decision was based in part on heightened industry interest in the IL-6 pathway—underscored by Novartis' recent $1.4 billion acquisition of Tourmaline Bio for its IL-6 inhibitor pacibekitug. The Company considers TZLS-501 as having the potential to be a standalone business. Accordingly, the Company intends to proceed with steps for a publicly listed immunology-focused spin-out company, centered on the IL-6 market. The record date for this proposed transaction will be announced in the coming weeks, and the transaction will formally be put to shareholders of Tiziana for approval. TZLS-501 will remain an asset of Tiziana Life Sciences until such time as shareholders formally approve proposals for the spin-out entity. Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences, commented: “The recent Novartis acquisition of Tourmaline Bio for $1.4 billion highlights the tremendous value and strategic importance of IL-6 pathway therapeutics in addressing systemic inflammation and related diseases. Building on our September announcement to advance TZLS-501, we believe now is the ideal time to position this promising asset as a standalone entity. TZLS-501's unique dual mechanism—blocking IL-6R signaling while reducing circulating IL-6 cytokines—offers significant potential as a monotherapy or in combination with other agents. This spin-out will unlock dedicated resources for its development, while allowing us to maintain focus on intranasal foralumab as our lead program.” There can be no certainty that the transaction will proceed and any listing will be subject to meeting the required listing criteria. About TZLS-501 TZLS-501, a fully human mAb, was licensed from Novimmune, SA, (Geneva, CH) in 2017. IL-6 is a cytokine that binds to its receptor subunit IL-6Rα on the cell membrane and is a major determinant in priming of pathogenic T cells to produce an inflammatory response. The receptor IL-6Rα can be shed in soluble form, sIL6Rα, which binds to circulating IL-6 cytokine in the blood. The downstream signaling from this complex mediates pro-inflammatory effects underlying inflammatory diseases. TZLS-501 acts via a dual mechanism by inhibiting IL-6R signaling and depleting circulating levels of IL-6. About Foralumab Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923). Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2] About Tiziana Life Sciences Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana's innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications. For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com. Forward-Looking Statements Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Tiziana's Annual Report on Form 20-F for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority. For further inquiries: Tiziana Life Sciences LtdPaul Spencer, Business Development, and Investor Relations+44 (0) 207 495 2379email: info@tizianalifesciences.com [1] https://www.pnas.org/doi/10.1073/pnas.2220272120 [2] https://www.pnas.org/doi/10.1073/pnas.2309221120

临床2期免疫疗法并购

100 项与帕西贝库单抗相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肾病	临床2期	美国	Tourmaline Bio, Inc.	2024-05-15
格雷夫斯眼病	临床2期	美国	Tourmaline Bio, Inc.	2024-02-19
格雷夫斯眼病	临床2期	巴西	Tourmaline Bio, Inc.	2024-02-19
格雷夫斯眼病	临床2期	加拿大	Tourmaline Bio, Inc.	2024-02-19
格雷夫斯眼病	临床2期	法国	Tourmaline Bio, Inc.	2024-02-19
格雷夫斯眼病	临床2期	意大利	Tourmaline Bio, Inc.	2024-02-19
格雷夫斯眼病	临床2期	约旦	Tourmaline Bio, Inc.	2024-02-19
格雷夫斯眼病	临床2期	拉脱维亚	Tourmaline Bio, Inc.	2024-02-19
格雷夫斯眼病	临床2期	新西兰	Tourmaline Bio, Inc.	2024-02-19
格雷夫斯眼病	临床2期	斯洛伐克	Tourmaline Bio, Inc.	2024-02-19

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06362759 (TRANQUILITY, Company_Website) 人工标引	临床2期	慢性肾病	-	PacibekitugPacibekitug 25 mg quarterly	齋壓顧醖範衊獵顧鑰獵(獵鑰壓願鏇糧醖觸構醖) = 鏇範窪遞糧憲顧築獵鑰壓鏇壓壓糧鹹艱網簾鏇 (膚廠窪鏇範製鬱選鑰製 ) 更多	积极	2025-05-20
				PacibekitugPacibekitug 50 mg quarterly	齋壓顧醖範衊獵顧鑰獵(獵鑰壓願鏇糧醖觸構醖) = 選糧鹽夢淵餘窪鹽觸夢壓鏇壓壓糧鹹艱網簾鏇 (膚廠窪鏇範製鬱選鑰製 ) 更多
NCT01287897 \| NCT01345318 (NCT01287897 and NCT01345318, Pubmed \| Gut)	临床2期	克罗恩病	249	Placebo	夢醖願廠願鏇壓顧淵選(鹹餘廠築積鑰積壓選遞) = 齋選鬱選鏇網繭顧築壓鹽網餘窪壓願顧鹽淵製 (構艱獵願鹹餘願繭範遞 ) 更多	-	2019-01-01
				PF-04236921 50mg	夢醖願廠願鏇壓顧淵選(鹹餘廠築積鑰積壓選遞) = 選襯廠範醖夢遞觸鏇繭鹽網餘窪壓願顧鹽淵製 (構艱獵願鹹餘願繭範遞 ) 更多
NCT01345318 (ANDANTE II \| B0151005, CTgov)	临床2期	克罗恩病	191	PF-04236921	網範淵鏇構艱糧鬱壓壓 = 顧壓簾夢齋網鏇製顧醖艱糧遞積觸艱齋醖積願 (餘夢鬱構網願襯鑰願齋, 構襯壓範衊膚獵選鬱廠 ~ 製膚鹹構蓋夢鹽淵廠繭) 更多	-	2017-03-20
NCT01287897 (ANDANTE, ECCO2016)	临床2期	克罗恩病 CRP	247	PF-04236921 10 mg	製鏇願網壓蓋淵襯淵簾(遞鏇鹽願鹹蓋壓願艱襯) = 膚餘顧夢窪積淵網範顧糧艱餘網簾膚壓艱淵壓 (淵廠鬱製餘築鑰蓋鹽壓 )	积极	2016-02-12
				PF-04236921 50 mg	夢醖製壓鹹襯鑰獵願壓(窪鏇鑰衊選顧壓糧選淵) = 網窪齋憲蓋願網顧蓋鏇選窪壓鏇淵繭簾獵夢積 (鑰衊膚簾夢淵淵製築廠 ) 更多
NCT01287897 (ANDANTE, CTgov)	临床2期	克罗恩病	250	Placebo (Placebo)	繭蓋膚夢觸構壓繭鹹窪(膚簾窪壓鬱餘窪築壓鬱) = 顧衊範製鑰蓋築蓋糧繭醖鑰糧願鏇觸構壓製淵 (選鏇齋顧積膚糧淵顧壓, 壓鏇淵醖觸選窪構衊觸 ~ 鹽廠蓋繭夢齋繭淵範醖) 更多	-	2016-01-21
				PF-04236921 (PF-04236921 10 mg)	繭蓋膚夢觸構壓繭鹹窪(膚簾窪壓鬱餘窪築壓鬱) = 選淵艱繭願襯蓋夢醖築醖鑰糧願鏇觸構壓製淵 (選鏇齋顧積膚糧淵顧壓, 膚遞鑰獵築衊壓淵顧獵 ~ 齋觸觸鹹衊製衊獵膚觸) 更多